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Abstract
Aims/hypothesis Many SNPs have been associated with
glycaemic traits and type 2 diabetes, but their joint effects on
glycaemic traits and the underlying mechanisms leading to
hyperglycaemia over time are largely unknown. We aimed
to investigate the association of six genetic risk scores
(GRSs) with changes in plasma glucose, insulin sensitivity,
insulin secretion and incident type 2 diabetes in the prospec-
tive METabolic Syndrome In Men (METSIM) study.
Methods We generated weighted GRSs for fasting plasma
glucose ([FPG] GRSFPG, 35 SNPs), 2 h plasma glucose
([2hPG] GRS2hPG, 9 SNPs), insulin secretion (GRSIS, 17
SNPs), insulin resistance (GRSIR, 9 SNPs) and BMI
(GRSBMI, 95 SNPs) and a non-weighted GRS for type 2 dia-
betes (GRST2D, 76 SNPs) in up to 8749 non-diabetic Finnish
men. Linear regression was used to test associations of the
GRSs with changes in glycaemic traits over time.
Results GRST2D, GRSFPG and GRSIS were associated with an
increase in FPG, GRST2D with an increase in glucose AUC
and a decrease in insulin secretion, and GRS2hPG with an
increase in 2hPG during the follow-up (p < 0.0017 for all
models). GRST2D, GRSFPG and GRSIS were associated with
incident type 2 diabetes (p < 0.008 for all models). GRSBMI
and GRSIR were not significantly associated with any changes
in glycaemic traits.
Conclusions/interpretation In the METSIM follow-up study,
GRST2D, GRSFPG and GRSIS were associated with the wors-
ening of FPG and an increase in incident type 2 diabetes.
GRST2D was additionally associated with a decrease in insulin
secretion, and GRS2hPG with an increase in 2hPG.
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Abbreviations
2hPG 2 h plasma glucose
FPG Fasting plasma glucose
GRS Genetic risk score
GRS2hPG GRS for 2hPG
GRSBMI GRS for BMI
GRSFPG GRS for FPG
GRSIR GRS for insulin resistance
GRSIS GRS for insulin secretion
GRST2D GRS for type 2 diabetes
ISI Index of insulin sensitivity
METSIM METabolic Syndrome In Men
Introduction
Genetic predisposition plays a crucial role in the risk of type 2
diabetes, in addition to environmental and lifestyle factors [1].
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As of 2016, genome-wide association studies had identified
~90 genetic loci associated with type 2 diabetes risk and >83
for glycaemic traits [2]. Several of the type 2 diabetes-
associated loci affect insulin secretion, and a smaller number
of loci affect insulin sensitivity [3]. A total of 97 loci have
been associated with BMI, an important risk factor for diabe-
tes [4].
The effects of individual genetic variants (SNPs) on the risk
of type 2 diabetes are generally small (odds ratio generally
1.15 or less), and therefore a genetic risk score (GRS) sum-
ming the effects of multiple risk alleles may provide a better
tool to estimate the risk for hyperglycaemia and type 2 diabe-
tes. Previous studies have reported that GRSs consisting of
11–65 diabetes-risk SNPs were associated with type 2 diabe-
tes [5–14]. Only a few studies have investigated the associa-
tions of GRSs for type 2 diabetes or related traits with changes
in glucose level [12, 15–17] or insulin secretion and sensitivity
[16, 18]. No prospective studies are available on the effects of
the GRS for insulin secretion or insulin resistance on plasma
glucose.
Determining type 2 diabetes as a dichotomous trait
may underestimate the effects of genetic variants on glu-
cose metabolism. Therefore, we investigated whether ge-
netic variants are associated with changes in plasma glu-
cose, insulin secretion and insulin resistance during the
4.6 year follow-up in non-diabetic individuals. To address
this aim, we generated GRSs for type 2 diabetes (GRST2D;
76 SNPs), fasting plasma glucose ([FPG] GRSFPG; 35
SNPs), 2 h plasma glucose ([2hPG] GRS2hPG; 9 SNPs),
insulin secretion (GRSIS; 17 SNPs), insulin resistance
(GRSIR; 9 SNPs) and BMI (GRSBMI; 95 SNPs), and in-
vestigated their association with plasma glucose, incident
type 2 diabetes and changes in insulin sensitivity and in-




TheMETSIM study comprises 10,197 Finnish men randomly
selected from the population register of Kuopio town, Eastern
Finland, aged from 45 to 73 years, examined in 2005–2010.
The study design has been described previously [19]. The
present report includes a subset of 8749 men without diabetes
at the baseline visit, confirmed by a 2 h OGTT (75 g glucose).
Glucose tolerance was evaluated according to ADA criteria
[20]. The study was approved by the Ethics Committee of the
University of Kuopio and Kuopio University Hospital. All
study participants gave written informed consent. Two datasets
from the METSIM study were used in this report, as presented
below.
Data for the prospective analysis of glycaemic traitsA total
of 5552 non-diabetic participants at baseline have so far par-
ticipated in the ongoing prospective METSIM study (mean
follow-up time ± SD: 4.6 ± 1.0 years) with the study protocol
and measurements identical to those of the baseline study.
Statistical analysis includes 5401 participants with OGTT data
(17 men with missing data excluded) and without type 2 dia-
betes diagnosed between the baseline and follow-up visits
(134 men excluded).
Data for the analysis of incident type 2 diabetes Among
8749 non-diabetic men at baseline, 693 developed incident
type 2 diabetes during follow-up (8.2 ± 1.8 years).
Diagnosis of new-onset type 2 diabetes was based on: (1)
FPG ≥ 7.0 mmol/l, 2hPG in an OGTT ≥11.1 mmol/l or
HbA1c ≥ 6.5% (47.5 mmol/mol) among 5552 non-diabetic
individuals who participated in the METSIM follow-up study
(n = 395); or (2) glucose-lowering medication started between
the baseline study and 31 December 2013 (n = 261; informa-
tion obtained from the National Drug Reimbursement registry
for all 8749 participants); or (3) diagnosis by a physician
based on medical records and/or FPG ≥ 7.0 mmol/l,
2hPG ≥ 11.1 mmol/l or HbA1c ≥ 6.5% in outpatient/primary
care laboratory measurements (n = 37). By aggregating data
from these three sources we were able to obtain information
about incident type 2 diabetes for all METSIM participants
with a longer follow-up time compared with the METSIM
follow-up study.
Clinical and laboratory measurements
Clinical and laboratory measurement methods have been pre-
viously published [19]. Briefly, plasma glucose was measured
by enzymatic hexokinase photometric assay (Konelab Systems
Reagents, Thermo Fischer Scientific, Vantaa, Finland). Insulin
was determined by immunoassay (ADVIA Centaur Insulin
IRI, no 02230141, Siemens Medical Solutions Diagnostics,
Tarrytown, NY, USA). HDL-cholesterol and total triacylglyc-
erol were measured by enzymatic colorimetric test (Konelab
Systems Reagents). Systolic and diastolic blood pressures were
calculated as an average of three measurements obtained with a
mercury sphygmomanometer.
Calculations
Glucose and insulin AUCs in an OGTTwere calculated by the
trapezoidal method. Matsuda index of insulin sensitivity (ISI)
[21] and the disposition index, a measure of insulin secretion
that is the product of an OGTT-based index of early-phase
insulin secretion (InsAUC0–30/GluAUC0–30) [19] and
Matsuda ISI, were calculated as previously described.
Genotyping and calculation of GRSs
A total of 216 SNPs were genotyped using either
HumanOmniExpress BeadChip-12v1 (Illumina, San Diego,
CA, USA; 733,202 markers) or HumanExome-12v1.1
Beadchip (Illumina, 247,870 markers). These SNPs were used
to generate GRSs based on previous publications [3, 4, 9, 22].
The list of SNPs or their proxies (r2 > 0.8, used for 62 of 216
SNPs, no proxies were found for 13 SNPs) with previously
published effect sizes in independent cohorts are given in
electronic supplementary material [ESM] Tables 1–6. We ad-
ditionally generated a GRS including 103 SNPs associated
with at least one of four traits (type 2 diabetes, FPG, 2hPG
and insulin secretion), and two GRSs combining SNPs asso-
ciated with more than one trait (ESM Table 7). Linkage dis-
equilibrium between the SNPs was tested using the online
SNAP 2.2 tool [23]. Genotypes for all 216 SNPs were consis-
tent with Hardy–Weinberg equilibrium at the significance lev-
el adjusted by Bonferroni method (0.05/216, p > 0.0002).
The GRSs were calculated for type 2 diabetes (76 SNPs for
8223 initially non-diabetic participants) (reviewed in
Stančáková and Laakso [24]), FPG (35 SNPs, n = 8562) and
2hPG (9 SNPs, n = 8610) [22], insulin secretion (17 SNPs,
n = 8550) [9], insulin resistance (9 SNPs, n = 8592) [9] and
BMI (95 SNPs, n = 8133) [4]. GRSFPG, GRS2hPG and
GRSBMI were weighted by previously published estimated
effect sizes on their respective traits [4, 22], and GRSIS and
GRSIRwere weighted for their previously published estimated
effect sizes on HOMA-beta and HOMA-IR indices [3, 9].
SNPs shown to be associated with other markers of insulin
secretion without available effect size on HOMA-beta could
not be included in the calculation of the GRSIS. For each
participant, the weighted GRSs were calculated as the sum
of the risk alleles of the SNPs included, where the number
of the risk alleles for each SNP was multiplied by the effect
size reported for that risk allele. The sum was divided by a
product of the sum of all effect sizes and the number of SNPs
to scale the GRSs back to the same scale as the unweighted
GRSs: GRSweighted = [(SNP1 × effect size1) + (SNP2 × effect
size2) + … + (SNPn × effect sizen)]/the sum of the effect
sizes × the number of the SNPs. We have additionally calcu-
lated a non-weighted GRS for each trait as the sum of the risk
alleles.
Statistical analysis
Statistical analyses were conducted using IBMSPSS Statistics
version 21 (Chicago, IL, USA). All continuous traits except
age, GRSs and change in BMI were log-transformed (inverse
normal transformation gave similar results) to correct for their
skewed distribution. Differences in characteristics between
the groups were tested using Student’s t test, and differences
between baseline and follow-up values by paired t test. Linear
regression was performed to test whether the GRSs predict
changes in continuous traits during follow-up. The model
was adjusted for age, BMI (except for the GRSBMI), current
smoking status (yes/no), and leisure-time physical activity
(active, regular exercise at least 30 min a week vs inactive,
occasional exercise or no exercise) at baseline, change in BMI
during follow-up (to account for the change in weight during
the follow-up), follow-up time (to account for the differences
in the follow-up time between the participants) and the base-
line level of the corresponding dependent trait. Results are
presented as effect sizes in the original units (B coefficient,
SE) or in SD units (β coefficient, SE) per one risk allele. All
p values were calculated using log-transformed variables, but
the effect sizes for FPG, 2hPG and glucose AUC were calcu-
lated using untransformed variables to obtain clinically mean-
ingful estimates in mmol/l. Cox regression was performed to
test the association of the GRSs with incident type 2 diabetes.
The adjustment was made for age, BMI (except for the
GRSBMI), smoking status and physical activity at baseline,
and additionally for systolic blood pressure, triacylglycerol
and HDL-cholesterol to account for confounding effects of
other risk factors for diabetes. Results are presented as an
HR (95% CI) per one risk allele. The level of statistical sig-
nificance was Bonferroni corrected for six GRSs (0.05/6,
p < 0.0083) and additionally for five glycaemic traits where
appropriate; p < 0.05 was considered as nominally significant.
To test whether the addition of the GRS into a prediction
model consisting of clinical risk factors for type 2 diabetes
(age, BMI, physical activity, smoking status, triacylglycerol,
HDL-cholesterol and systolic blood pressure) improves the
prediction of type 2 diabetes, we compared the AUCs of the
receiver operating characteristic (ROC) curves of the models
with and without the GRS.
Results
Characteristics of the study participants
Table 1 gives characteristics and the GRSs for 8749 partici-
pants who did (n = 693) or did not (n = 8056) develop type 2
diabetes during the 8.2 year follow-up, and characteristics at
the baseline and 4.6 year follow-up for a subset of 5401 par-
ticipants without diabetes at baseline and during follow-up
who had an OGTT at both visits. At baseline, the participants
who developed type 2 diabetes were significantly older, had
higher BMI, higher glucose levels, lower disposition index
and Matsuda ISI, were more often smokers and physically
inactive, and carried a significantly higher number of the risk
alleles for type 2 diabetes, FPG, 2hPG and insulin secretion
than those who did not develop diabetes. The participants of
the METSIM follow-up study had significantly higher BMI
and glucose levels, and lower disposition index and Matsuda
ISI at the follow-up compared with the baseline examination,
although their lifestyle variables improved (reduction in the
percentage of smoking and physical inactivity).
Associations of GRSs with changes in glycaemic traits
in the prospective analysis
Each of the calculated GRSs was significantly associated with
its corresponding trait in the cross-sectional METSIM study
(all p < 0.0001, ESM Table 8). For example, each allele of the
GRSFPG and GRS2hPG increased the levels of FPG and 2hPG
by 0.025 and 0.087 mmol/l, respectively.
In the prospective analysis adjusted for age, smoking status
and physical activity at baseline, baseline BMI and change in
BMI during follow-up (except for the GRSBMI) and the
follow-up time (Fig. 1, ESM Table 9), the GRST2D was sig-
nificantly (0.05/6 GRSs × 5 traits, p < 0.0017) associated with
an increase in FPG (the effect size per a risk allele
B = 0.007 mmol/l), glucose AUC (B = 1.35 mmol/l × min),
and with a decrease in the disposition index (standardised
effect estimate β = −0.008) during the 4.6 year follow-up.
The GRSFPG was significantly associated with an increase in
FPG (B = 0.010 mmol/l), and nominally (p < 0.05) with an
increase in the glucose AUC (B = 0.356 mmol/l × min), and a
decrease in the disposition index (β = −0.007) during follow-
up. The GRS2hPG was significantly associated with an
increase in 2hPG (B = 0.048 mmol/l) during follow-up.
However, the associations between the GRSFPG or GRS2hPG
and changes in their respective glucose levels were clinically
minor.
GRSIS was significantly associated with an increase in FPG
(B = 0.008 mmol/l) and nominally with a decrease in the
disposition index (β = −0.011) during the follow-up. GRSIR
and GRSBMI were not significantly associated with changes in
any of the traits. Unadjusted analyses showed similar but
slightly weaker associations (ESM Table 9). We additionally
performed these analyses using non-weighted GRSs and ob-
tained very similar results (data not shown).
None of the 216 SNPs included in the GRSs was signifi-
cantly associated with changes in plasma glucose, insulin se-
cretion or insulin resistance during follow-up in 5335 partici-
pants (p < 4.2 × 10−5 corrected for 216 SNPs × 5 traits; ESM
Table 10).
Associations of GRSs with incident type 2 diabetes
GRST2D, GRSFPG and GRSIS were significantly (p < 0.0083
adjusted for six GRSs) associated with an increased risk of
incident type 2 diabetes during an 8.2 year follow-up by 4%,
3% and 4% per risk allele, respectively, in an unadjusted mod-
el (Table 2). The GRS2hPG was nominally associated and
GRSIR and GRSBMI were not significantly associated with
Table 1 Baseline clinical, laboratory characteristics and GRSs of the participants of the METSIM study who did or did not develop type 2 diabetes
during the mean 8.2 year follow-up period, and changes in clinical and laboratory characteristics during the 4.6 year follow-up in participants without
previously diagnosed diabetes
Characteristic Baseline characteristics of the entire cohort (n = 8749) Subset with OGTT at follow-up (n = 5401)
No diabetes Incident type 2 diabetes p Baseline Follow-up p
n Mean SD n Mean SD n Mean SD Mean SD
Age (years) 8056 57.1 7.08 693 58.6 6.83 2 × 10−8 5401 57.8 7.01 62.4 6.89
BMI (kg/m2) 8053 26.6 3.70 693 29.2 4.24 2 × 10−50 5401 26.5 3.47 26.8 3.71 <0.001
FPG (mmol/l) 8056 5.68 0.46 693 6.12 0.48 3 × 10−112 5401 5.68 0.47 5.76 0.56 <0.001
2hPG (mmol/l) 8056 5.92 1.60 693 7.52 1.98 2 × 10−77 5401 5.97 1.60 6.16 2.02 <0.001
Disposition index 8007 168.4 71.56 690 106.7 47.32 2 × 10−172 5321 167.5 71.0 162.2 75.0 <0.001
Matsuda ISI 8007 7.12 4.16 690 4.52 3.17 5 × 10−88 5321 7.17 4.08 6.40 4.31 <0.001
Current smokers (%) 8056 17.9 693 21.5 0.020 5388 14.2 11.7 <0.001
Physical inactivity (%) 8056 34.2 693 43.3 1 × 10−6 5400 32.5 29.6 <0.001
GRST2D (76 SNPs)
a 7568 77.6 5.36 655 78.8 5.37 2 × 10−7
GRSFPG (35 SNPs)
b 7880 38.0 4.05 682 38.5 3.94 0.001
GRS2hPG (9 SNPs)
b 7928 7.47 1.78 682 7.62 1.85 0.044
GRSIS (17 SNPs)
b 7869 18.6 2.70 681 18.9 2.69 0.003
GRSIR (9 SNPs)
b 7909 9.29 1.93 683 9.40 1.92 0.164
GRSBMI (95 SNPs)
b 7484 88.1 6.05 649 88.5 6.01 0.095
Glucose and insulin levels at 30 min of an OGTT, needed to calculate the disposition index and Matsuda ISI, were missing for 80 participants
a Non-weighted GRS
bWeighted GRS
incident type 2 diabetes. After adjustment for age, BMI,
smoking status and physical activity at baseline the associa-
tion of GRS2hPG became significant and other associations
slightly strengthened. Further adjustment including additional
risk factors for diabetes (baseline levels of systolic blood
pressure, triacylglycerol and HDL-cholesterol) did not essen-
tially affect the results. The risk of incident diabetes was
11.3% in the highest decile (≥ 85 risk alleles) compared with
5.4% in the lowest decile (≤ 70 risk alleles) of GRST2D
(Fig. 2a), and FPG increased by 0.1 mmol/l in the highest
decile compared with 0.06 mmol/l in the lowest decile during
the 4.6 year follow-up (Fig. 2b).
Based on the above results we generated an additional GRS
combining SNPs associated with type 2 diabetes, FPG, 2hPG
and insulin secretion (103 SNPs, SNPs associated with more
than one trait or in linkage disequilibrium were only included
once, preferably the SNP associated with type 2 diabetes,
ESM Table 7). This 103-SNP GRS was significantly associ-
ated with incident type 2 diabetes in all models tested
(Table 2).
Adding GRST2D into a prediction model consisting of clin-
ical risk factors for type 2 diabetes such as age, BMI, physical
activity, smoking status, triacylglycerol, HDL-cholesterol and
systolic blood pressure only slightly improved the prediction
of type 2 diabetes (AUC increased from 0.711 to 0.719,
p = 0.053), whereas adding the combined 103-SNP GRS to
the clinical model improved the prediction of type 2 diabetes
significantly (AUC 0.721, p = 0.010).
We tested all 216 individual SNPs for the association with
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Fig. 1 Associations of GRST2D, GRSFPG, GRS2hPG, GRSIS, GRSIR and
GRSBMI with longitudinal changes in FPG (a), 2hPG (b), glucose AUC
in an OGTT (c), insulin secretion (disposition index; d) and insulin sen-
sitivity (Matsuda ISI; e) in the 4.6 year prospective METSIM study
(maximum of 5329 men without previously diagnosed diabetes; see also
ESM Table 9). Results are adjusted for baseline age, smoking status,
physical activity, baseline BMI and change in BMI during follow-up
(except for the GRS of BMI) and the follow-up time. *Nominally signif-
icant (p < 0.05); ††significant (p < 0.0017). aNon-weighted GRS;
bweighted GRS
genotypes but none of the associations was statistically signif-
icant (p < 2.3 × 10−4, 0.05/216) (ESM Table 11). Nominally
significant associations (p < 0.05) were observed for type 2
diabetes-associated SNPs in TCF7L2 and THADA, and sever-
al BMI-associated SNPs, where the BMI-increasing allele was
associated with either higher (SNPs in/near ETV5, ETS2,
GRP, PRKD1, EHBP1) or lower (SNPs in/near KCNK3,
KCTD15, FUBP1, MC4R, LOC100287559) risk of incident
diabetes.
GRSs including shared SNPs
Several GRSs showing significant associations with incident
type 2 diabetes and changes in glycaemic traits during the
follow-up share several SNPs (or different SNPs from the
same genetic loci, mostly representing proxies) (ESM
Table 12). We additionally generated two GRSs combining
SNPs associated with two (18 SNPs) or all three (8 SNPs) of
the following traits: type 2 diabetes, FPG and insulin secretion
(ESMTable 7). The 18-SNPGRSwas significantly associated
with incident type 2 diabetes, and both 18-SNP and 8-SNP
GRSswere significantly or nominally associatedwith changes
in FPG, glucose AUC and insulin secretion over time. This
suggests that the overlapping SNPs contribute to the
associations observed for the GRST2D, GRSFPG and GRSIS
(Table 2 and ESM Table 9).
Discussion
The main findings of our prospective study are that: (1)
GRST2D, GRSFPG andGRSISwere significantly associatedwith
an increase in FPG during the follow-up, and GRST2D was
additionally significantly associated with changes in the
glucose AUC and insulin secretion (disposition index); (2)
GRS2hPG was associated with an increase in 2hPG level; (3)
GRST2D, GRSFPG andGRSISwere significantly associatedwith
the incident type 2 diabetes; and (4) GRSBMI and GRSIR were
not significantly associated with changes in glycaemic traits.
GRSFPG and GRS2hPG
Identifying individuals at high risk of developing type 2
diabetes is critical for effective prevention of this disease.
Glucose levels are the strongest predictors for type 2 dia-
betes [1, 25], but none of the previous studies has inves-
tigated the association of genetic variants with glucose
AUC in an OGTT (based on 0, 30 and 120 min glucose
Table 2 Associations of GRSs with incident type 2 diabetes in an 8.2 year follow-up of the METSIM study
Predictor Total/cases, n Unadjusted Adjusted 1 Adjusted 2
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Individual trait GRS
GRST2D (76 SNPs)
a 8223/655 1.04 (1.02, 1.05) 1.7 × 10–7†† 1.05 (1.03, 1.06) 1.0 × 10–9†† 1.05 (1.03, 1.06) 4.4 × 10–10††
GRSFPG (35 SNPs)
b 8562/682 1.03 (1.01, 1.05) 0.001†† 1.04 (1.02, 1.06) 6.2 × 10–5†† 1.04 (1.02, 1.06) 5.4 × 10–5††
GRS2hPG (9 SNPs)
b 8610/682 1.04 (1.00, 1.09) 0.040* 1.06 (1.02, 1.11) 0.007†† 1.06 (1.01, 1.10) 0.009†
GRSIS (17 SNPs)
b 8550/681 1.04 (1.02, 1.07) 0.002†† 1.06 (1.03, 1.09) 1.4 × 10–4†† 1.06 (1.03, 1.09) 6.7 × 10–5††
GRSIR (9 SNPs)
b 8592/683 1.03 (0.99, 1.07) 0.166 1.04 (1.00, 1.08) 0.058 1.04 (1.00, 1.08) 0.041*
GRSBMI (95 SNPs)
b 8133/649 1.01 (1.00, 1.02) 0.090 1.01 (1.00, 1.02) 0.072 1.01 (1.00, 1.02) 0.175
Combined traits GRS
4 traits (103 SNPs)a 7804/627 1.03 (1.02, 1.04) 2.7 × 10–6†† 1.04 (1.02, 1.05) 1.2 × 10–8†† 1.04 (1.03, 1.05) 4.0 × 10–9††
2–3 traits (18 SNPs)a 8582/682 1.05 (1.02, 1.08) 0.0016†† 1.06 (1.03, 1.09) 1.7 × 10–4†† 1.06 (1.03, 1.09) 7.1 × 10–5††
3 traits (8 SNPs)a 8605/684 1.03 (0.99, 1.08) 0.146 1.04 (0.99, 1.08) 0.111 1.04 (0.99, 1.08) 0.106
The six main GRSs could be calculated for 8133–8610 participants, depending on the availability of SNPs
Data from three Cox regression models are presented: unadjusted, adjusted for age, BMI (all except for the GRS for BMI), smoking status and physical
activity (adjusted model 1); and additionally adjusted for systolic blood pressure, HDL-cholesterol and triacylglycerol levels (adjusted model 2)
HRs (95% CI) per risk allele are shown
*Nominally significant (p < 0.05)
†† Statistically significant at the level of p < 0.0083 (0.05/6 main GRSs)
a Non-weighted GRS
bWeighted GRS
GRS 4 traits combines the SNPs associated with at least one of the following traits: type 2 diabetes, FPG, 2hPG and insulin secretion; GRS 2–3 traits
combines the SNPs associated with at least two of type 2 diabetes, FPG and insulin secretion and GRS 3 traits combines the SNPs associated with all
three of type 2 diabetes, FPG and insulin secretion
levels), which reflects the total ‘glucose burden’ on pan-
creatic beta cells. A Swedish study showed that a 16-SNP
GRS for FPG was associated with higher FPG levels
(0 .030 mmol/ l per GRS uni t ) and 2hPG levels
(0.026 mmol/l per GRS unit) at baseline, and an elevation
of FPG levels from baseline to follow-up [26]. Another
study reported an association of a 16-SNP GRS for FPG
with higher FPG levels (0.029 mmol/l per GRS unit) that
remained consistent over time, and an association of a 5-
SNP GRS fo r 2hPG wi th h ighe r 2hPG leve l s
(0.076 mmol/l per GRS unit) which became stronger with
increasing age [15]. Our study demonstrated that the
GRSFPG (35 SNPs) and the GRS2hPG (9 SNPs) had similar
effect sizes on FPG (0.025 mmol/l per GRS unit) and
2hPG (0.087 mmol/l per GRS unit) levels at baseline,
respectively, as in earlier studies [15, 26]. Moreover, the
GRSFPG and the GRS2hPG were significantly associated
with further increases in FPG (by 0.010 mmol/l per GRS
unit) and 2hPG (by 0.048 mmol/l per GRS unit), respec-
tively, and nominally with an increase in glucose AUC
during the follow-up, even after correcting for baseline
age, BMI, smoking status, physical activity, correspond-
ing baseline glucose level, change in BMI during the fol-
low-up, and follow-up time. Finally, both GRSFPG and
GRS2hPG were associated with an increased risk of inci-
dent type 2 diabetes, in contrast to a previous study using
a 24-SNP GRS for FPG that did not show significant
association [12]. These findings suggest that genetic fac-
tors predict increases in glucose levels and glucose AUC,
explaining, at least in part, the conversion to type 2 dia-
betes. However, these effects may be too modest to be
clinically relevant.
GRSIS and GRSIR
In our study, GRSIS was significantly associated with an
increase in FPG, a decrease in disposition index (nomi-
nally significant) and an increased risk of incident type 2
diabetes during follow-up. These findings emphasise the
central role of impaired insulin secretion in the conversion
to diabetes. By contrast, GRSIR did not significantly pre-
dict changes in FPG or 2hPG, or the conversion to diabe-
tes. This is consistent with a previous study [9] and sug-
gests that insulin resistance is mostly acquired (weight
gain, lack of exercise, unhealthy diet), and not genetically
determined to the extent of insulin secretion [25].
However, a previous large study (18,565 individuals in-
cluding 8124 incident cases of diabetes) demonstrated that
the GRS for insulin resistance was associated with inci-
dent type 2 diabetes [27], which may indicate that our
study was underpowered to demonstrate this association.
GRST2D
Our GRST2D including 76 SNPs was significantly associated
with an increased risk of incident type 2 diabetes that was
higher by twofold in the highest decile compared with the
lowest decile. Accordingly, FPG was increased by
0.1 mmol/l in the highest decile compared with a
0.06 mmol/l increase in the lowest decile during the 4.6 year
follow-up. The increase in the risk of diabetes was 5% per
GRST2D unit in the adjusted model, which is slightly less than
the 8% reported in a previous study using a 62-SNP GRS for
type 2 diabetes [9], and in studies including a lower number of
type 2 diabetes-associated SNPs [5–13, 16, 28].
Only a few previous studies have investigated the associa-
tions of diabetes-associated SNPs with longitudinal changes
in glycaemic traits [15–16, 26, 29]. A Danish study using a
GRS based on 46 diabetes-associated SNPs reported a signif-
icant increase in glucose levels in an OGTT and a decrease in
OGTT-based insulin secretion indices and the disposition in-
dex per risk allele during a 5 year follow-up [16]. In a 9 year





























































































Fig. 2 (a) Conversion to type 2 diabetes (%) during an 8.2 year follow-
up in 8223 METSIM participants without diabetes at entry according to
GRST2D decile. Number of individuals in each decile group: (1) 726; (2)
1040; (3) 955; (4) 597; (5) 603; (6) 1269; (7) 567; (8) 936; (9) 716; and
(10) 814. (b) Change in fasting glucose during a 4.6 year follow-up in
5076 participants without previously diagnosed diabetes according to
GRST2D decile. Number of individuals in each decile group: (1) 471;
(2) 630; (3) 592; (4) 381; (5) 386; (6) 763; (7) 343; (8) 590; (9) 423;
and (10) 497
associated SNPs predicted deterioration in beta cell function
but not insulin sensitivity (assessed by the OGTT-based indi-
ces) [18]. Our results of the associations of GRST2D with
incident diabetes and with changes in glucose levels (FPG,
glucose AUC) and insulin secretion during the follow-up are
consistent with these results.
GRSBMI
Obesity is an important risk factor for diabetes. Our study did
not show significant association of GRSBMI (95 SNPs) with
incident type 2 diabetes and changes in plasma glucose, insu-
lin secretion (disposition index) or insulin sensitivity
(Matsuda ISI) during the follow-up. In the GLACIER study,
no significant association of a 97-SNP GRS for BMI was
observed with FPG or 2hPG during a 10 year follow-up
[29]. By contrast, a cross-sectional Chinese study reported that
a GRS consisting of 30 BMI-associated SNPs significantly
increased the risk of type 2 diabetes [30].
The strength of our study is that it investigates several
GRSs relevant for glucose metabolism for associations with
trait changes over time in a single population. It shows that
although the GRSs specific for FPG and 2hPG are the best
predictors of the changes in the respective glucose levels, the
GRS for type 2 diabetes, including the highest number of risk
variants published so far, significantly predicts changes in
several traits including fasting glucose, glucose AUC, insulin
secretion and incident type 2 diabetes. Nevertheless, it con-
tributed relatively little to a diabetes-prediction model that
includes clinical risk factors, similar to previous studies in-
cluding a smaller number of SNPs [5, 9, 11, 28], suggesting
that the clinical relevance of the current GRSs remains limited.
However, the SNPs used in the current analyses were origi-
nally identified in cross-sectional studies, and longitudinal
studies may provide more knowledge of the genetics of trait
changes over time. Furthermore, including a larger number of
SNPs in the GRSs will likely improve their predictive ability,
as supported by our observation that the combined 103-SNP
GRS significantly improved the prediction of type 2 diabetes.
Other strengths of our study are a large and homogeneous
population, detailed phenotyping including measures of insu-
lin secretion and insulin resistance at both baseline and follow-
up examinations, and extensive genotyping, which allowed us
to use the most complete up-to-date genetic associations with
type 2 diabetes and related traits. A limitation of our study is
that, as we included only Finnish men, we cannot ensure the
applicability of our results to women or other populations.
In conclusion, our study demonstrates that GRST2D,
GRSFPG and GRSIS predicted the worsening of FPG and in-
cident type 2 diabetes, with GRST2D also predicting adverse
changes in insulin secretion. These GRSs provide a useful tool
to estimate the effects of multiple risk alleles on the develop-
ment of hyperglycaemia and type 2 diabetes.
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